Combination tacrolimus and ustekinumab therapy is effective in inducing clinical, biochemical and endoscopic remission in refractory moderate to severe ulcerative colitis

Autoimmun Rev. 2022 Jul;21(7):103115. doi: 10.1016/j.autrev.2022.103115. Epub 2022 May 17.

Authors

Rachit Gupta¹, Julien D Schulberg², Ola Niewiadomski², Emily K Wright²

Affiliations

¹ St Vincent's Hospital Melbourne Pty Ltd, Gastroenterology, 41 Victoria Parade, Fitzroy AUS 3065, Australia. Electronic address: ritchie.gupta26@gmail.com.
² St Vincent's Hospital Melbourne Pty Ltd, Gastroenterology, 41 Victoria Parade, Fitzroy AUS 3065, Australia.

PMID: 35595052
DOI: 10.1016/j.autrev.2022.103115

No abstract available

Publication types

Letter
Comment

MeSH terms

Colitis, Ulcerative* / drug therapy
Humans
Immunosuppressive Agents / therapeutic use
Remission Induction
Tacrolimus* / therapeutic use
Treatment Outcome
Ustekinumab / therapeutic use

Substances

Immunosuppressive Agents
Ustekinumab
Tacrolimus